Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand.
AIDS Patient Care STDS. 2010 Mar;24(3):141-6. doi: 10.1089/apc.2009.0314.
Neurocognitive outcome is an essential aspect of treatment for HIV-infected children. This study is aimed at assessing cognitive functioning in school-aged HIV-infected children and the change after receiving antiretroviral therapy (ART). We conducted a prospective cohort study of HIV-infected Thai children from 6-12 years of age compared with HIV-affected (children of HIV-positive mothers who were not infected with HIV), and normal control groups. Wechsler Intelligence Scale for Children-III (WISC-III) was administered at enrollment and 30 months of follow-up. Semistructured interviews of primary caregivers were performed. From April to October 2003, 121 children were enrolled; 39 HIV-infected, 40 HIV-affected, and 42 control children with a median age of 9.3 years. The HIV-infected group had a mean (standard deviation [SD]) CD4 percentage of 13.8% (5.3), 87% of whom had been receiving ART for a median of 35 weeks. At the first cognitive assessment, the mean (SD) of full-scale intelligence quotient (FSIQ) was 79 (13) and 88 (10) among HIV-infected and HIV-affected children, which was statistically lower than that of the control group at 96 (13; p < 0.01). The proportion of children with average intelligence level (FSIQ > 90) among 3 groups were 21%, 49%, and 76%, respectively (p < 0.01). At 30 months of follow-up, the HIV-infected group had a mean (SD) CD4 percentage of 25.6% (5.6); 77% had undetectable viral load. The mean (SD) FSIQ of children among three groups were 75 (12), 85 (12), and 91 (12), respectively. Compared with the baseline assessment, the verbal scale score significantly decreased in all groups, including the controls, whereas the performance scales did not change. In conclusion, school-aged HIV-infected children have lower cognitive function than HIV-affected and normal children. Cognitive function was not improved after receiving ART. Further study to address whether early ART can preserve cognitive functioning among HIV-infected children should be explored.
神经认知结果是治疗 HIV 感染儿童的一个重要方面。本研究旨在评估学龄期 HIV 感染儿童的认知功能,以及接受抗逆转录病毒治疗(ART)后的变化。我们对来自泰国的 6-12 岁 HIV 感染儿童进行了一项前瞻性队列研究,将其与 HIV 受影响的儿童(HIV 阳性母亲所生但未感染 HIV 的儿童)和正常对照组进行了比较。我们在入组时和 30 个月随访时使用了韦氏儿童智力量表第三版(WISC-III)。对主要照顾者进行了半结构式访谈。2003 年 4 月至 10 月期间,共纳入 121 名儿童;其中 39 名 HIV 感染,40 名 HIV 受影响,42 名正常对照,中位年龄为 9.3 岁。HIV 感染组的 CD4 百分比的平均值(标准差[SD])为 13.8%(5.3),其中 87%的儿童已经接受了中位数为 35 周的 ART。在第一次认知评估时,HIV 感染和 HIV 受影响儿童的全量表智商(FSIQ)平均值(SD)分别为 79(13)和 88(10),明显低于对照组的 96(13;p<0.01)。3 组中智力正常水平(FSIQ>90)的儿童比例分别为 21%、49%和 76%(p<0.01)。30 个月随访时,HIV 感染组的 CD4 百分比平均值(SD)为 25.6%(5.6);77%的儿童病毒载量不可检测。3 组儿童的 FSIQ 平均值(SD)分别为 75(12)、85(12)和 91(12)。与基线评估相比,所有组,包括对照组,言语量表评分均显著下降,而操作量表评分没有变化。总之,学龄期 HIV 感染儿童的认知功能低于 HIV 受影响和正常儿童。接受 ART 后认知功能没有改善。应进一步研究早期 ART 是否能维持 HIV 感染儿童的认知功能。